RESUMO
Background: Multiple features in the presentation of randomized controlled trial (RCT) results are known to influence comprehension and interpretation. We aimed to compare interpretation of cancer RCTs with time-to-event outcomes when the reported treatment effect measure is the hazard ratio (HR), difference in restricted mean survival times (RMSTD), or both (HR+RMSTD). We also assessed the prevalence of misinterpretation of the HR. Methods: We carried out a randomized experiment. We selected 15 cancer RCTs with statistically significant treatment effects for the primary outcome. We masked each abstract and created three versions reporting either the HR, RMSTD, or HR+RMSTD. We randomized corresponding authors of RCTs and medical residents and fellows to one of 15 abstracts and one of 3 versions. We asked how beneficial the experimental treatment was (0-10 Likert scale). All participants answered a multiple-choice question about interpretation of the HR. Participants were unaware of the study purpose. Results: We randomly allocated 160 participants to evaluate an abstract reporting the HR, 154 to the RMSTD, and 155 to both HR+RMSTD. The mean Likert score was statistically significantly lower in the RMSTD group when compared with the HR group (mean difference -0.8, 95% confidence interval, -1.3 to -0.4, P < 0.01) and when compared with the HR+RMSTD group (difference -0.6, -1.1 to -0.1, P = 0.05). In all, 47.2% (42.7%-51.8%) of participants misinterpreted the HR, with 40% equating it with a reduction in absolute risk. Conclusion: Misinterpretation of the HR is common. Participants judged experimental treatments to be less beneficial when presented with RMSTD when compared with HR. We recommend that authors present RMST-based measures alongside the HR in reports of RCT results.
Assuntos
Neoplasias/mortalidade , Sistemas On-Line/estatística & dados numéricos , Ensaios Clínicos Controlados Aleatórios como Assunto , Terapia Combinada , Humanos , Neoplasias/patologia , Neoplasias/terapia , Prognóstico , Taxa de Sobrevida , Fatores de TempoRESUMO
The cleistogamous species Collomia grandiflora produces dimorphic cross-incompatible flowers on a single plant. The open or chasmogamous flower has smaller, flask-shaped stigmatic papillae, larger pollen grains, longer styles, and faster pollen tube growth rates down the style than the closed or cleistogamous flower. In intermorph crosses, pollen tube growth rates are greatly decreased and fertilization does not occur.
RESUMO
The secretory matrix of the stylar-transmitting tract of angiosperms has been characterized as a nutrient medium for the growth of pollen tubes, acting to guide tubes to the ovules. When nonliving particles (latex beads) were artificially introduced onto the transmitting tracts of styles of Hemerocallis flava, Raphanus raphanistrum, and Vicia faba, they were translocated to the ovary at rates similar to those of pollen tubes. Direct observations were made on the movement of individual beads along the secretory epidermis in the style and ovary of Vicia faba. The transmitting tract may play an active role in extending tube tips to their destination in the ovary.
RESUMO
Observations of malic acid fluctuation, leaf anatomy, and stable carbon isotopic composition showed that the epiphytic strangler Clusia rosea, growing on Saint John, U.S. Virgin Islands, has crassulacean acid metabolism. This hemiepiphyte may be the only woody dicotyledonous tree species among the many thousands of flowering species in the 30 or more plant families that shows this type of metabolism. The finding has implications with respect to water balance during the process whereby Clusia rosea establishes itself as a tree, since crassulacean acid metabolism is a photosynthetic adaptation to water-stressed environments.
RESUMO
Significant numbers of myocytes die by apoptosis during myocardial infarction. The molecular mechanism of this process, however, remains largely unexplored. To facilitate a molecular genetic analysis, we have developed a model of ischemia-induced cardiac myocyte apoptosis in the mouse. Surgical occlusion of the left coronary artery results in apoptosis, as indicated by the presence of nucleosome ladders and in situ DNA strand breaks. Apoptosis occurs mainly in cardiac myocytes, and is shown for the first time to be limited to hypoxic regions during acute infarction. Since hypoxia-induced apoptosis in other cell types is dependent on p53, and p53 is induced by hypoxia in cardiac myocytes, we investigated the necessity of p53 for myocyte apoptosis during myocardial infarction. Myocyte apoptosis occurs as readily, however, in the hearts of mice nullizygous for p53 as in wild-type littermates. These data demonstrate the existence of a p53-independent pathway that mediates myocyte apoptosis during myocardial infarction.
Assuntos
Apoptose , Genes p53/fisiologia , Infarto do Miocárdio/patologia , Miocárdio/patologia , Animais , Hipóxia Celular , DNA/análise , Genes p53/genética , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Fatores de TempoRESUMO
The extracellular matrix (ECM) has been implicated in the primary developmental processes of many organisms. A family of secretory adhesive glycoproteins called substrate adhesion molecules (SAMs) is believed to confer these dynamic capabilities to the ECM in animals. In this paper, we report the existence of SAM-like genes and gene products in flowering plants. Hybridizations with a human vitronectin cDNA probe and genomic DNA from broad bean, soybean, and tomato revealed vitronectin-like sequences. Human vitronectin antibodies cross-react with a 55-kilodalton protein in leaf and root protein extracts from lily, broad bean, soybean, and tomato. In addition, immunocytochemical staining of frozen sections of lily leaf and broad bean gynoecium demonstrated that vitronectin-like proteins were localized to the ECM on the cell surface, with the most intense labeling residing in the transmitting tract of broad bean gynoecium.
RESUMO
Dimethyl sulfoxide (DMSO) has previously been shown to increase the surface expression of H-2K and H-2D antigens on cultured line 1 carcinoma cells. H-2 densities increase from initial levels barely detectable with flow cytometry to those found on normal BALB/c spleen cells. Here we compare the susceptibilities of untreated and DMSO-treated line 1 cells to lysis mediated by H-2d specific monoclonal antibodies and complement, cytotoxic T-cells, and natural killer cells. Induced H-2 antigens appear to function normally in that DMSO-treated cells are highly susceptible to all types of H-2 restricted immune lysis, whereas untreated line 1 cells are not. DMSO does not increase lysis of line 1 cells mediated by natural killer cells. Our results suggest that DMSO could be used to make the growth of major histocompatibility complex antigen-deficient tumors more sensitive to T-cell-mediated immunological resistance.
Assuntos
Carcinoma/imunologia , Dimetil Sulfóxido/farmacologia , Antígenos H-2/imunologia , Neoplasias Pulmonares/imunologia , Animais , Antígenos de Neoplasias/imunologia , Citotoxicidade Imunológica/efeitos dos fármacos , Isoanticorpos/imunologia , Células Matadoras Naturais/imunologia , Camundongos , Linfócitos T/imunologiaRESUMO
Hypoxic cells in tissue pose many medical problems, and there is a need for more accurate measurements of tissue hypoxia. However, measurement of the pO2 and the extent of hypoxia within normal and tumor tissue have proven difficult. One of the most sensitive of the currently available methodologies involves the oxygen-dependent metabolic activation of nitroheterocyclic drugs, leading to adducts between the drugs and cellular macromolecules. Limitations of the present drugs and adduct-detection methods prompted the present studies. A pentafluorinated derivative [EF5; 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetam ide] of etanidazole was synthesized with the expectation of lessening some of the non-oxygen-dependent variability in adduct formation observed previously with other nitroaromatic compounds. EF5-protein conjugates, prepared by radiochemical reduction, were found to be immunogenic and allowed the development of monoclonal antibodies. One of these antibodies, ELK2-4, has been characterized and found to be highly specific for the EF5 adducts whether produced radiochemically or by cellular bioreductive metabolism. 9L rat glioma cells pretreated with EF5 under hypoxic, compared with aerobic, conditions were readily discriminated immunochemically using fluorochrome-conjugated secondary antibodies which recognize the ELK2-4 antibody subtype (IgG1). Similarly, the central region of multicenter spheroids, composed of EMT6 mouse mammary sarcoma cells, was selectively visualized by immunohistochemistry after the spheroids were incubated for 4 h in 0.5 mM EF5. Tumor biopsy, preparation, and immunohistochemical staining 24 h after treatment of tumor-bearing animals with drug also demonstrated high contrast regions within EMT6 mouse or Morris 7777 hepatoma rat tumors. The use of this new compound and its highly specific monoclonal antibody may allow elucidation of bioreductive metabolism of the nitroheterocyclics and significantly improve technologies for the quantitation of tissue pO2.
Assuntos
Anticorpos Monoclonais , Hipóxia Celular , Etanidazol/análogos & derivados , Nitroimidazóis/metabolismo , Animais , Etanidazol/síntese química , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Nitroimidazóis/imunologiaRESUMO
Previous reports have established that line 1, a spontaneous BALB/c lung carcinoma, expresses a Mr 180,000 tumor-associated surface antigen (TSP-180). In this study, using a monoclonal antibody and flow cytometry to quantify cell surface TSP-180 expression, we found that essentially all cells in a tissue culture-adapted line 1 population express TSP-180, but that the amount of TSP-180 expressed by cells is quite heterogeneous. Variation in amount of TSP-180 was found to be in part related to cell size heterogeneity, and to the expression of TSP-180 being cell cycle-dependent. The amount of surface-expressed TSP-180 correlated somewhat with cell size, and was greater on the average for cells in the G2 cell cycle compartment. However, cells of a defined size and specific cell cycle stage still showed marked heterogeneity of expression. Even though the average amount of TSP-180 expressed per cell decreased during in vitro propagation, little change in heterogeneity was observed. To explore whether any TSP-180-related heterogeneity resulted from heritable variation of expression, 263 limiting dilution-derived line 1 clones were analyzed. The majority displayed, shortly after cloning, heterogeneous TSP-180 profiles and mean TSP-180 levels similar to those observed for the parent tumor. Occasionally, however, clones were isolated that again appeared as heterogeneous as the parent, but differed by as much as 3-fold in mean TSP-180 expression. Extensive passage did not substantially increase the low probability of isolating clones which differed in expression of TSP-180. Differences in TSP-180 expression among clones were found to be relatively stable upon passage, typically maintained after recloning, and large enough to influence clonal susceptibility to TSP-180-directed antibody and complement-mediated lysis. Heritable variation in TSP-180 expression among some clones was also shown to be independent of differences related to cell size, cell cycle, or expression of another line 1 surface antigen (P-100). We concluded that although clones demonstrating large heritable differences in TSP-180 expression can occasionally be isolated, line 1 TSP-180 heterogeneity is predominantly nonheritable, being similar to that present in recently cloned lines, quite stable during in vitro passage, and not totally accounted for by cell cycle or cell size variation.
Assuntos
Antígenos de Neoplasias/análise , Antígenos de Superfície/análise , Neoplasias Pulmonares/imunologia , Animais , Anticorpos Monoclonais , Ciclo Celular , Linhagem Celular , Membrana Celular/imunologia , Células Clonais , Citometria de Fluxo , Imunofluorescência , Cinética , Camundongos , Camundongos Endogâmicos BALB C , Peso MolecularRESUMO
Microenvironmental conditions within solid tumors can have marked effects on the growth of the tumors and their response to therapies. The disorganized growth of tumors and their attendant vascular systems tends to result in areas of the tumors that are deficient in oxygen (hypoxic). Cells within these hypoxic areas are more resistant to conventional therapies such as radiation and chemotherapy. Here, we examine the hypoxic state of EMT6 mouse mammary tumors and the location of host cells within the different areas of the tumors to determine whether such microenvironmental conditions might also affect their ability to be recognized by the immune system. Hypoxia within tumors was quantified by flow cytometry and visualized by immunohistochemistry using a monoclonal antibody (ELK3-51) against cellular adducts of 2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetam ide (EF5), a nitroimidazole compound that binds selectively to hypoxic cells. Thy-1+ cells, quantified using a monoclonal antibody, were found only in the well-oxygenated areas. The location of these Thy-1+ cells was also examined in EMT6 tumors that had been transfected with the gene for interleukin-2 (IL-2) because these tumors contain greatly increased numbers of host cells. Surprisingly, we found that IL-2-transfected tumors had significantly decreased hypoxia compared to parental tumors. Furthermore, using the fluorescent dye Hoechst 33342, an in vivo marker of perfused vessels, combined with immunochemical staining of PECAM-1 (CD31) as a marker of tumor vasculature, we found increased vascularization in the IL-2-transfected tumors. Thus, expression of IL-2 at the site of tumor growth may enhance tumor immunity not only by inducing the generation of tumor-reactive CTLs but also by allowing increased infiltration of activated T cells into the tumors.
Assuntos
Anticorpos Antineoplásicos/biossíntese , Interleucina-2/fisiologia , Neoplasias Mamárias Experimentais/imunologia , Neoplasias Mamárias Experimentais/metabolismo , Animais , Hipóxia Celular , Interleucina-2/biossíntese , Interleucina-2/genética , Linfócitos do Interstício Tumoral/imunologia , Linfócitos do Interstício Tumoral/fisiologia , Neoplasias Mamárias Experimentais/irrigação sanguínea , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos DBA , TransfecçãoRESUMO
We investigated the effects that mouse interleukin 3 (IL-3), in comparison to mouse IL-2, has on the generation of cytotoxic effectors capable of killing line 1 tumor cells. These potent immunological mediators were delivered locally using gene transfection, rather than systemically, to the tumor site. We created line 1 transfectants that express high levels of IL-3 (3750 units/ml) or IL-2 (200 units/ml) by driving transcription from the beta-actin promoter. These levels of expression significantly enhanced tumor rejection in syngeneic mice. Tumor-infiltrating lymphocytes purified from IL-3 or IL-2 transfected tumors showed a dramatically enhanced cytotoxic response to parental line 1 targets. Also, IL-2, but not IL-3, expression enhanced the nonspecific lysis of YAC-1 cells. In vivo depletion of CD8+ cells with monoclonal antibody 2.43 abrogated the generation of cytotoxic effectors in both cases. Interestingly, depletion of CD4+ cells with monoclonal antibody GK1.5 abrogated the IL-3-mediated cytotoxic response but not the IL-2-mediated response. In vivo depletion of CD4+ or CD8+ cells abrogated the effect IL-3 had on reducing tumorigenicity. Reverse polymerase chain reaction analysis demonstrates that IL-3 transfected tumors, when compared to untransfected tumors, express increased levels of IL-2 and IL-4 mRNA. These results strongly suggest that IL-3, unlike IL-2, works to generate cytotoxic effectors by a mechanism that requires CD4+ cells.
Assuntos
Carcinoma/imunologia , Citotoxicidade Imunológica , Imunidade Celular , Interleucina-3/farmacologia , Neoplasias Pulmonares/imunologia , Linfócitos do Interstício Tumoral/imunologia , Subpopulações de Linfócitos T/imunologia , Animais , Linfócitos T CD4-Positivos/imunologia , Antígenos CD8/análise , Carcinoma/patologia , Expressão Gênica , Técnicas In Vitro , Interleucina-2/genética , Interleucina-4/genética , Neoplasias Pulmonares/patologia , Camundongos , Camundongos Endogâmicos BALB C , RNA Mensageiro/genética , RNA Neoplásico/genética , Transfecção , Células Tumorais CultivadasRESUMO
The presence of hypoxic tumor cells is known to be an important cause of radiation treatment resistance in vivo. The ability to predict the presence and extent of hypoxic cells in individual tumors would allow the addition of specific "antihypoxia"-based treatment regimes. Hypoxia can be monitored by measuring the binding of 2-nitroimidazoles. We have tested the hypothesis that binding of EF5, a fluorinated derivative of the 2-nitroimidazole, Etanidazole, can predict radioresistance in individual tumors. Fischer rats bearing 9L s.c. tumors were given injections i.v. with EF5 3 h before irradiation and tumor harvest. Tumor cells were dissociated for flow cytometric analysis and plating efficiency studies. EF5 binding was detected via monoclonal antibodies conjugated to the orange emitting dye, Cy3. In air breathing rats, for a given radiation dose, a large amount of variation in plating efficiency was seen. However, there was minimal variability of the plating efficiency for tumors irradiated in euthanized animals (hypoxic tumors; correlation coefficient for the fitted curve = 0.93) and in cells dissociated from tumors and irradiated in suspension (correlation coefficient for the fitted curve = 0.99), suggesting that varying sensitivity to the cell disaggregation technique was not responsible. In contrast, a good correlation between the relative radiation resistance or hypoxic survival and EF5 binding of "moderately" hypoxic cells in air breathing rats was identified using these techniques. In these 9L s.c. tumors, intertumor variation in oxygenation accounted for most of the range in individual tumor radiation response, and this was found to be independent of tumor size. This study provides evidence for the application of EF5 binding with monoclonal antibody detection as an in vivo predictive assay of individual tumor hypoxia and resultant therapy resistance.
Assuntos
Antineoplásicos/metabolismo , Etanidazol/análogos & derivados , Glioma/metabolismo , Glioma/radioterapia , Hidrocarbonetos Fluorados/metabolismo , Tolerância a Radiação , Animais , Anticorpos Monoclonais , Hipóxia Celular , Etanidazol/metabolismo , Valor Preditivo dos Testes , RatosRESUMO
We have investigated the hypoxia inducibility of vascular endothelial growth factor (VEGF) in multicellular tumor spheroids of HT29 cells using a monoclonal antibody to a fluorinated bioreductive drug, EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)aceta mide], a chemical probe for hypoxia. We have shown that VEGF expression is predominantly localized in interior spheroid cells that are sufficiently hypoxic to bioreductively activate the 2-nitroimidazole and produce immunologically detectable adducts of the EF5 compound. Northern blotting analyses demonstrated that VEGF165 is the predominant form of VEGF produced by HT29 cells and that the phorbol ester 12-O-tetradecanoyl-phorbol-13-acetate did not induce VEGF expression. This study demonstrates that VEGF expression is up-regulated in response to hypoxia and in the microenvironments found in human multicellular tumor spheroids. This investigation also illustrates the utility of the EF5 binding in multi-cellular tumor spheroids as a means of studying the expression and regulation of hypoxia-inducible genes.
Assuntos
Carcinoma/irrigação sanguínea , Neoplasias do Colo/irrigação sanguínea , Fatores de Crescimento Endotelial/genética , Linfocinas/genética , Neovascularização Patológica , Etanidazol/análogos & derivados , Regulação Neoplásica da Expressão Gênica , Humanos , Hidrocarbonetos Fluorados , Hipóxia/metabolismo , Hibridização In Situ , Indicadores e Reagentes , Organoides , RNA Mensageiro/genética , RNA Neoplásico/genética , Células Tumorais Cultivadas , Fator A de Crescimento do Endotélio Vascular , Fatores de Crescimento do Endotélio VascularRESUMO
The role of angiogenesis inhibition in the antitumor activity of recombinant murine interleukin 12 (rmIL-12) was studied in K1735 murine melanomas, the growth of which is rapidly and markedly suppressed by rmIL-12 treatment. On the basis of the prediction that tumor ischemia should result from therapeutic angiogenesis inhibition, tumor cell hypoxia was evaluated as a marker of ischemia using the EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)aceta mide] approach. This method measures intracellular binding of the nitroimidazole EF5, which covalently binds to cellular macromolecules selectively under hypoxic conditions. Whereas 1 week of rmIL-12 treatment effectively inhibited K1735 cell-induced angiogenesis in Matrigel neovascularization assays, 2 weeks of treatment were needed before severe tumor cell hypoxia was detected in K1735 tumors. The hypoxia that developed was regional and localized to tumor areas distant from blood vessels. The great majority of severely hypoxic tumor cells were apoptotic, and in vitro studies indicated that the degree of hypoxia present within treated tumors was sufficient to trigger K1735 apoptosis. Tumor cell apoptosis was also prevalent in the first week of rmIL-12 treatment when few cells were hypoxic. In vitro studies indicated that this non-hypoxia-related apoptosis was induced directly by IFN-gamma produced in response to rmIL-12 administration. These studies reveal that rmIL-12 controls K1735 tumors initially by IFN-gamma-induced apoptosis and later by hypoxia-induced apoptosis. They also establish hypoxia as an expected result of tumor angiogenesis inhibition and a mediator of its therapeutic effect.
Assuntos
Apoptose/fisiologia , Hipóxia Celular/fisiologia , Interleucina-12/uso terapêutico , Melanoma Experimental/irrigação sanguínea , Melanoma Experimental/patologia , Neovascularização Patológica/prevenção & controle , Animais , Apoptose/efeitos dos fármacos , Hipóxia Celular/efeitos dos fármacos , Colágeno , Combinação de Medicamentos , Feminino , Interferon gama/farmacologia , Isquemia , Laminina , Melanoma Experimental/tratamento farmacológico , Camundongos , Camundongos Endogâmicos C3H , Proteoglicanas , Proteínas Recombinantes/uso terapêutico , Células Tumorais CultivadasRESUMO
Localization and quantitation of 2-nitroimidazole drug binding in low pO2 tumors is a technique that can allow the assessment of hypoxia as a predictive assay. EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide] is such a drug, and it has been shown to be predictive of radiation response in rodent tumors. Using fluorescence immunohistochemical techniques, we provide data on the presence, distribution, and levels of EF5 binding as a surrogate for hypoxia in human head and neck and uterine cervix squamous cell cancers (SCCs). Six patients with SCC were studied. Four patients had head and neck tumors, and two had uterine cervix cancers. The incubation of fresh tissue cubes in EF3 under hypoxic conditions ("reference binding") demonstrated that all tumors were capable of binding drug, and that this binding varied by a factor of 2.9-fold (174.5-516.1) on an absolute fluorescence scale. In the five patients treated at the lowest drug doses (9 mg/kg), in situ binding was quantitatable. For all six patients, the maximum rate of in situ binding varied by a factor of 6.7 between the lowest and highest binding tumor (24.8-160.3) on an absolute fluorescence scale. In tumors with high binding regions, intratumoral heterogeneity was large, extending from minimal fluorescence (<1%) up to 88.6% of reference binding. In tumors with minimal binding, there was little intratumoral heterogeneity. These studies demonstrate substantial heterogeneity of in situ binding between and within individual squamous cell tumors.
Assuntos
Antineoplásicos/farmacocinética , Carcinoma de Células Escamosas/patologia , Hipóxia Celular , Etanidazol/análogos & derivados , Neoplasias de Cabeça e Pescoço/patologia , Hidrocarbonetos Fluorados/farmacocinética , Neoplasias do Colo do Útero/patologia , Adulto , Idoso , Antineoplásicos/efeitos adversos , Antineoplásicos/uso terapêutico , Sítios de Ligação , Carcinoma de Células Escamosas/tratamento farmacológico , Etanidazol/efeitos adversos , Etanidazol/farmacocinética , Etanidazol/uso terapêutico , Feminino , Neoplasias de Cabeça e Pescoço/tratamento farmacológico , Humanos , Hidrocarbonetos Fluorados/efeitos adversos , Hidrocarbonetos Fluorados/uso terapêutico , Masculino , Pessoa de Meia-Idade , Neoplasias do Colo do Útero/tratamento farmacológicoRESUMO
Vanadium associates with serum transferrin of rats administered vanadyl(IV) sulfate or ammonium metavanadate(V) by gastric intubation. Low molecular weight species account for only 3% of the vanadium present in plasma. The element distributes between the two major isotransferrins in proportion to their concentrations. Rat apotransferrin binds both vanadium(IV) and vanadium(V), forming 2:1 metal-protein complexes in both instances. Although the two isotransferrins apparently differ in their physiological properties, they exhibit identical vanadyl(IV) (VO2+) EPR spectra, indicating identical or very similar metal binding sites for both proteins. In contrast to other transferrins, the two sites of the rat protein are spectroscopically indistinguishable and exhibit a VO2+ EPR spectrum similar to that of the C-terminal metal binding site of human serum transferrin. VO2+ EPR signals are observed with liver, spleen, and kidney tissue samples from animals maintained on a vanadium-supplemented diet. These signals arise from a specific intracellular VO2+ complex with the iron storage protein ferritin.
Assuntos
Ferritinas/sangue , Transferrina/metabolismo , Vanádio/sangue , Animais , Sítios de Ligação , Densitometria , Espectroscopia de Ressonância de Spin Eletrônica , Feminino , Rim/metabolismo , Fígado/metabolismo , Masculino , Ratos , Ratos Endogâmicos , Baço/metabolismoRESUMO
INTRODUCTION: Defects in placental angiogenesis and spiral artery remodeling have been proposed to play essential roles in the development of preeclampsia. However, the specific molecular mechanism(s) responsible for aberrant placental angiogenesis in preeclampsia are incompletely understood. The vascular endothelial growth factor receptors (VEGFR1, R2, R3) and STAT3 have critical functions in normal blood vessel development, but their potential roles in preeclampsia are currently unclear. In this study, we utilized a novel whole mount immunofluorescence (WMIF) method to compare expression of VEGFR1, R2, R3 and activated, phosphorylated STAT3 (pSTAT3) in placentas of preeclamptic (PE) versus normotensive (NT) pregnancies. METHODS: Placental biopsies collected from NT and PE pregnant women were fixed and stained with fluorochrome-conjugated antibodies to identify specific cell populations as follows: CD31 for blood vessel endothelial cells, cytokeratin-7 for trophoblast cells, and CD45 for immune cells. Expression of the VEGFRs and pSTAT3 were subsequently characterized by WMIF in conjunction with confocal microscopy. RESULTS: A total of 18 PE and 18 NT placentas were evaluated. No significant differences in the cell type-specific expression patterns or expression levels of VEGFR1, VEGFR2 or VEGFR3 were detected between NT and PE placentas. In contrast, statistically significant increases in pSTAT3 staining were detected in endothelial cells of PE placentas versus NT controls. DISCUSSION: Our study demonstrates that increased pSTAT3 expression in placental endothelial cells is associated with PE. We speculate that elevated pSTAT3 expression in the blood vessels of PE placentas may be due to aberrant angiogenesis, increased pro-inflammatory cytokine expression, and/or placental stress.
Assuntos
Placenta/metabolismo , Pré-Eclâmpsia/metabolismo , Receptores de Fatores de Crescimento do Endotélio Vascular/metabolismo , Fator de Transcrição STAT3/metabolismo , Estudos de Casos e Controles , Feminino , Imunofluorescência , Humanos , GravidezRESUMO
There is currently much interest in generating cytotoxic T lymphocyte (CTL) responses against tumor antigens as a therapy for cancer. This work describes a novel gene transfer technique utilizing dendritic cells (DCs), an extremely potent form of antigen-presenting cell (APC), and herpes simplex virus-1 (HSV-1) amplicons. HSV-1 amplicons are plasmid-based viral vectors that are packaged into HSV-1 capsids, but lack viral coding sequences. Amplicon vectors have been constructed that encode the model tumor antigen ovalbumin (HSV-OVA) and human prostate-specific antigen (HSV-PSA), a protein that is expressed specifically in prostate epithelium and prostate carcinoma cells. These amplicons were packaged using a helper virus-free system that produces vector stocks that are devoid of contaminating cytotoxic helper virus. Transduction of DCs with HSV-OVA or HSV-PSA and co-culture with CTL hybridomas results in specific activation, indicating that transduced DCs express these transgenes and process the tumor antigens for class I MHC presentation to CTL. Mice immunized with HSV-PSA-transduced DCs generate a specific CTL response that can be detected in vitro by a (51)Cr-release assay and are protected from challenge with tumors that express PSA. These results indicate that DCs transduced with HSV-1 amplicon vectors may provide a tool for investigation of the biology of CTL activation by DCs and a new modality for immunotherapy of cancer.
Assuntos
Vacinas Anticâncer , Células Dendríticas/citologia , Células Dendríticas/metabolismo , Herpesvirus Humano 1/genética , Imunoterapia/métodos , Neoplasias/terapia , Antígeno Prostático Específico/biossíntese , Animais , Células Apresentadoras de Antígenos/metabolismo , Linhagem Celular , Radioisótopos de Cromo/metabolismo , Técnicas de Cocultura , Células Epiteliais/metabolismo , Citometria de Fluxo , Vetores Genéticos , Proteínas de Fluorescência Verde , Humanos , Hibridomas , Proteínas Luminescentes/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Endogâmicos C57BL , Plasmídeos/metabolismo , Neoplasias da Próstata/metabolismo , Fatores de Tempo , Transdução GenéticaRESUMO
Direct antigen presentation of tumor-associated antigens by tumor cells to T lymphocytes may induce clonal anergy as a mechanism of escape from immune surveillance. B7-1 is a costimulatory molecule for the activation of both CD4+ and CD8+ T lymphocytes that prevents the induction of clonal anergy. Thus, the transfer of B7-1 genes into tumor cells can induce protective immunity and lead to tumor rejection of some tumors in model systems of in vivo tumor growth; however, there is no information on whether stable expression of B7-1 can affect the in vivo growth of squamous cell carcinoma, a common skin cancer. Here, we study how the stable cell surface expression of high levels of B7-1 by Pam 212, a murine squamous cell carcinoma, affects tumor cell-lymphocyte interactions (lymphocyte proliferation and cytotoxicity). Consistent with its costimulatory role, we demonstrate that B7-1 can efficiently induce dendritic epidermal T-cell proliferation in three different dendritic epidermal T-cell cell lines. In addition, B7-1 enhances dendritic epidermal T-cell cytolytic activity against Pam 212 cells in an in vitro 51Cr-release assay, which was blocked by CTLA-4/Ig fusion protein. In contrast to dendritic epidermal T cells, the expression of B7-1 does not alter Pam 212 interactions with either cytotoxic T-lymphocytes, natural killer, or lymphokine-activated killer cells. B7-1 expression by Pam 212 cells did not alter its ability to grow tumors in vivo, as their rate of tumor growth was the same as vector-transfected Pam 212 cells, which were B7-1 negative. Our studies indicate that B7-1 gene transfer into Pam 212 does not alter its tumorigenicity, because it does not alter tumor cell-lymphocyte interactions with cytotoxic T lymphocytes, natural killer cells, and lymphokine-activated killer cells. Further studies of B7-1 modified Pam 212 and dendritic epidermal T cells will clarify whether T-cell receptor-gamma/delta-bearing T lymphocytes can play a role in immunotherapy of Pam 212 squamous cell carcinoma.
Assuntos
Antígeno B7-1/fisiologia , Carcinoma de Células Escamosas/patologia , Comunicação Celular , Células Dendríticas/fisiologia , Linfócitos T/fisiologia , Animais , Antígeno B7-1/análise , Carcinoma de Células Escamosas/imunologia , Divisão Celular , Feminino , Células Matadoras Ativadas por Linfocina/imunologia , Células Matadoras Naturais/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Nus , Linfócitos T Citotóxicos/imunologiaRESUMO
Malignant cells and non-neoplastic host cells were isolated from in vivo growing solid tumors of 2 BALB/c transplantable tumors: EMT6/Ro, a mammary sarcoma, and Line 1, an alveolar cell carcinoma. The technique of centrifugal elutriation was used to separate these 2 major types of cells present within solid tumors. In addition it was found that 2 successive passages through the elutriator of the cells from the tumors resulted in a better separation of the host cells into lymphocyte and macrophage populations than was possible by an optimally designed single passage. Thus this technique can provide sufficient host cells, essentially devoid of malignant cells, for further functional analysis.